Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Additionally, while FOXO4-DRI has been shown to limit chemotoxicity in certain contexts, its overall safety profile in humans requires further research to fully understand all potential side effects
doi: 10.26442/00403660.2019.01.000040 Sato F, Omura T, Ishimaru M, Endo Y, Murase H, Yamashita E
Most patients run an initial protocol of three to six months before reassessment
The amino acid sequence is the same compound that Eli Lilly has published, but the research-grade material supplied here is not equivalent to Eli Lilly's investigational drug product, is not produced under the same regulatory framework, and is not a substitute for any clinical trial supply, compounded preparation, or future approved formulation
